TCRX

TScan Therapeutics, Inc.

6.72 USD
-0.04 (-0.59%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

TScan Therapeutics, Inc. stock is up 34.94% since 30 days ago. The next earnings date is Mar 6, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 71.43% of the previous 9 February’s closed higher than January. 100% of analysts rate it a buy.

About TScan Therapeutics, Inc.

TScan Therapeutics, Inc. develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2.